Amrize Faces Mixed Analyst Signals: Truist Downgrades, Wells Fargo Holds Overweight
Amrize faces contrasting analyst actions, with Truist Securities downgrading the stock from Buy to Hold and cutting the price target to $48 from $65, while Wells Fargo's Timna Tanners retains an Overweight rating but lowers the price target from $65 to $58, signaling a cautious yet relatively constructive outlook from the latter.

*this image is generated using AI for illustrative purposes only.
Amrize is receiving divergent signals from Wall Street, as two prominent analysts revise their outlooks on the stock. Truist Securities analyst Keith Hughes has downgraded Amrize from Buy to Hold, slashing the price target to $48 from $65. Meanwhile, Wells Fargo analyst Timna Tanners maintains an Overweight rating but also trims the price target from $65 to $58, reflecting a more cautious near-term view while retaining a broadly positive stance on the stock.
Analyst Ratings and Price Target Summary
The following table outlines the latest analyst actions on Amrize:
| Analyst Detail: | Truist Securities | Wells Fargo |
|---|---|---|
| Analyst: | Keith Hughes | Timna Tanners |
| Previous Rating: | Buy | Overweight |
| New Rating: | Hold | Overweight |
| Previous Price Target: | $65 | $65 |
| New Price Target: | $48 | $58 |
Diverging Perspectives
The Truist Securities downgrade represents a more significant shift in sentiment, moving Amrize entirely out of the Buy category and signaling reduced confidence in the stock's near-term upside. The revised price target of $48 marks a substantial decline from the prior $65 target. In contrast, Wells Fargo's decision to maintain its Overweight rating suggests continued long-term conviction in the stock, even as the lowered price target of $58 acknowledges potential headwinds. Together, these actions reflect a broader recalibration of expectations around Amrize's valuation among institutional analysts.
What specific near-term headwinds prompted the significant reduction in price targets by both analysts?
How might the divergence in analyst ratings impact institutional investor sentiment toward Amrize?
What factors could drive Wells Fargo to maintain its Overweight rating despite lowering its price target?

























